rosiglitazone has been researched along with Central Nervous System Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Y; Huang, Y; Li, R; Li, Y; Sun, H; Yang, J; Yu, X; Zhao, G | 1 |
1 other study(ies) available for rosiglitazone and Central Nervous System Diseases
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats.
Topics: Animals; Benzamides; Blotting, Western; Brain Injuries; CD40 Antigens; Central Nervous System Diseases; Enzyme-Linked Immunosorbent Assay; Epilepsy; Hippocampus; Immunohistochemistry; Inflammation; Lithium Compounds; Male; Pilocarpine; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; Rosiglitazone; Seizures; Status Epilepticus; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2008 |